AAPS PharmSciTech

, Volume 19, Issue 3, pp 1264–1273 | Cite as

Enhancement of In Vivo Efficacy and Oral Bioavailability of Aripiprazole with Solid Lipid Nanoparticles

  • Silki
  • Vivek Ranjan Sinha
Research Article


Aripiprazole (ARP), a second-generation or atypical antipsychotic, is poorly soluble and undergoes extensive hepatic metabolism and P-glycoprotein efflux which lead to reduced in vivo efficacy and increased dose-related side effects. To enhance in vivo efficacy and oral bioavailability of aripiprazole, aripiprazole-loaded solid lipid nanoparticles (SLNs) were developed using tristearin as solid lipid. Tween 80 and sodium taurocholate were used as surfactants to prepare SLNs using microemulsification method. SLNs were characterized for particle size, zeta potential, entrapment efficiency, and crystallinity of lipid and drug. In vitro release studies were performed in water containing 0.5% sodium dodecyl sulfate. Pharmacodynamic evaluation was carried out in laca mice using dizocilpine-induced schizophrenic model where behavioral evaluation revealed better in vivo efficacy of SLNs. Pharmacokinetics of aripiprazole-loaded SLNs after oral administration to conscious male Wistar rats was studied. Bioavailability of aripiprazole was increased 1.6-fold after formulation of aripiprazole into SLNs as compared to plain drug suspension. The results indicated that solid lipid nanoparticles can improve the bioavailability of lipophilic drugs like aripiprazole by enhancement of absorption and minimizing first-pass metabolism.


aripiprazole solid lipid nanoparticles antischizophrenic solid lipid nanoparticles bioavailability enhancement dizocilpine-induced schizophrenia 



The authors are thankful to Unichem Laboratories, India for providing aripiprazole samples ex-gratis

Funding Information

The current research work was funded by AICTE, New Delhi, India (vide sanction no. 20/AICTE/RIFD/RPS (POLICY-1)27/2012-13).

Compliance with Ethical Standards

The study was previously approved by Institutional Animal Ethics Committee (IAEC, UIPS, Panjab University, Chandigarh). The experiments were conducted as per CPCSEA guidelines (Committee for Prevention, Control, and Supervision of Animal Experiments).

Supplementary material

12249_2017_944_Fig9_ESM.gif (101 kb)

(GIF 101 kb)

12249_2017_944_MOESM1_ESM.tif (74 kb)
High resolution image (TIFF 74 kb)
12249_2017_944_Fig10_ESM.gif (95 kb)

(GIF 94 kb)

12249_2017_944_MOESM2_ESM.tif (17 kb)
High resolution image (TIFF 16 kb)
12249_2017_944_Fig11_ESM.gif (96 kb)

(GIF 96 kb)

12249_2017_944_MOESM3_ESM.tif (22 kb)
High resolution image (TIFF 22 kb)
12249_2017_944_Fig12_ESM.gif (123 kb)

(GIF 123 kb)

12249_2017_944_MOESM4_ESM.tif (78 kb)
High resolution image (TIFF 78 kb)
12249_2017_944_Fig13_ESM.gif (184 kb)

(GIF 184 kb)

12249_2017_944_MOESM5_ESM.tif (75 kb)
High resolution image (TIFF 74 kb)


  1. 1.
    Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P&T®. 2014;39 (9):638–345.Google Scholar
  2. 2.
    Wig NN, Varma VK, Mattoo SK, Bedi HS. An incidence study of schizophrenia in India. Indian J Psychiatry. 1993;35(1):11–7.Google Scholar
  3. 3.
    Sawant K, Pandey A, Patel S. Aripiprazole loaded poly(caprolactone) nanoparticles: optimization and in vivo pharmacokinetics. Mater Sci Eng C. 2016;66:230–43. Scholar
  4. 4.
    Mathews M, Muzina DJ. Atypical antipsychotics: new drugs, new challenges. Cleve Clin J Med. 2007;74(8):597–605. Scholar
  5. 5.
    Oh Y, Choi G, Choy YB, Park JW, et al. Aripiprazole_montmorillonite: a new organic–inorganic nanohybrid material for biomedical applications. Chem Eur J. 2013;19(15):4869–75. Scholar
  6. 6.
    Ying X, Liu X, Lian R, Zheng S, Yin Z, Lu Y, et al. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. Int J Pharm. 2012;438(1–2):287–95. Scholar
  7. 7.
    Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8(11):1407–24. Scholar
  8. 8.
    Raza K, Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topical treatment of acne. Colloids Surf B: Biointerfaces. 2013;105:67–74.
  9. 9.
    Maghsoudi A, Shojaosadati SA, Farahani EV. 5-Fluorouracil-loaded BSA nanoparticles: formulation optimization and in vitro release study. AAPS PharmSciTech. 2008;9(4):1092–6. Scholar
  10. 10.
    Zhang C, Gu C, Peng F, Liu W, Wan J, Xu H, et al. Preparation and optimization of triptolide-loaded solid lipid nanoparticles for oral delivery with reduced gastric irritation. Molecules. 2013;18(11):13340–56. Scholar
  11. 11.
    Negi JS, Chattopadhyay P, Sharma AK, Ram V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur J Pharm Sci. 2013;48(1-2):231–9. Scholar
  12. 12.
    Pandita D, Ahuja A, Lather V, Benjamin B, Dutta T, Velpandian T, et al. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSciTech. 2011;12(2):712–22. Scholar
  13. 13.
    Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62–76. Scholar
  14. 14.
    Singh S, Dobhal AK, Jain A, Pandit JK, Chakraborthy A. Formulation and evaluation of solid lipid nanoparticles of water soluble drug: zidovudine. Chem Pharm Bull. 2010;58(5):650–5. Scholar
  15. 15.
    Wang W, Chen L, Huang X, Shao A. Preparation and characterization of minoxidil loaded nanostructured lipid carriers. AAPS PharmSciTech. 2017;18(2):509–16. Scholar
  16. 16.
    Sood S, Jawahar N, Jain K, Gowthamarajan K, Meyyanathan SN. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci. 2013;9:26–34.Google Scholar
  17. 17.
    Kalam MA, Sultana Y, Ali A, Aqil M, Mishra AK, Chuttani K. Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system. J Drug Target. 2010;18(3):191–204. Scholar
  18. 18.
    Rehman M, Madni A, Ihsan A, Khan WS, Khan MI, Mahmood MA, et al. Solid and liquid lipid-based binary solid lipid nanoparticles of diacerein: in vitro evaluation of sustained release, simultaneous loading of gold nanoparticles, and potential thermoresponsive behavior. Int J Nanomedicine. 2015;10:2805–14. Scholar
  19. 19.
    Tiyaboonchai W, Tungpradit W, Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int J Pharm. 2007;337(1-2):299–306. Scholar
  20. 20.
    Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release. 2006;114(1):53–9. Scholar
  21. 21.
    Kelidari HR, Saeedi M, Akbari J, Morteza-semnani K, Valizadeh H, Maniruzzaman M, et al. Development and optimisation of spironolactone nanoparticles for enhanced dissolution rates and stability. AAPS PharmSciTech. 2017;18(5):1469–74. Scholar
  22. 22.
    Wang W, Zhu R, Xie Q, Li A, Xiao Y, Li K, et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine. 2012;7:3667–77. Scholar
  23. 23.
    Kumar VV, Chandrasekar D, Ramakrishna S, Kishan V, Rao YM, Diwan PV. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335(1-2):167–75. Scholar
  24. 24.
    Carvalhoa SM, Noronha CM, Floriani CL, Linoa RC, Rocha G, et al. Optimization of α-tocopherol loaded solid lipid nanoparticles by central composite design. Ind Crop Prod. 2013;49:278–85. Scholar
  25. 25.
    Aburahma MH, Badr-Eldin SM. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin Drug Deliv. 2014;11(12):1865–83. Scholar
  26. 26.
    Alexa MR, Aji CAJ, Josea S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42(1-2):11–8. Scholar
  27. 27.
    Dhir A, Naidu PS, Kulkarni SK. Modulatory effect of nimesulide on apomorphine induced stereotypy and mk-801 induced hyperlocomotion. Ann Neurosci. 2005;12(4):71–3. Scholar
  28. 28.
    Yee BK, Singer P. A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia. Cell Tissue Res. 2013;354(1):221–46. Scholar
  29. 29.
    Pedersen CS, Sørensen DB, Parachikova A, Plath N. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia. Behav Brain Res 2014; 15: 273:63–72. doi:
  30. 30.
    Lee SH, Lee MG. Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm. 1996;24(6):551-568.Google Scholar
  31. 31.
    Metsugi Y, Miyaji Y, Ogawara K, Higaki K, Kimura T. Appearance of double peaks in plasma concentration–time profile after oral administration depends on gastric emptying profile and weight function. Pharm Res. 2008;25(4):886–95. Scholar
  32. 32.
    Yang S, Zhu J, Lu Y, Liang B, Liang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16(5)Google Scholar
  33. 33.
    Hallan SS, Nidhi, Kaur V, Jain V, Mishra N. Development and characterization of polymer lipid hybrid nanoparticles for oral delivery of LMWH. Artif Cells Nanomed Biotechnol. 2017:1–12.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  1. 1.University Institute of Pharmaceutical SciencesPanjab UniversityChandigarhIndia

Personalised recommendations